Biological convergence of cancer signatures

dc.contributor.authorSolé Acha, Xavier
dc.contributor.authorBonifaci Cano, Núria
dc.contributor.authorLópez Bigas, Núria
dc.contributor.authorBerenguer, Antoni
dc.contributor.authorHernández, Pilar
dc.contributor.authorReina, Oscar
dc.contributor.authorMaxwell, Christopher A.
dc.contributor.authorAguilar, Helena
dc.contributor.authorUrruticoechea Ribate, Ander
dc.contributor.authorSanjosé Llongueras, Silvia de
dc.contributor.authorComellas, Francesc
dc.contributor.authorCapellá, G. (Gabriel)
dc.contributor.authorMoreno Aguado, Víctor
dc.contributor.authorPujana Genestar, M. Ángel
dc.date.accessioned2016-03-03T11:12:01Z
dc.date.available2016-03-03T11:12:01Z
dc.date.issued2009-02-20
dc.date.updated2016-03-02T07:46:22Z
dc.description.abstractGene expression profiling has identified cancer prognostic and predictive signatures with superior performance to conventional histopathological or clinical parameters. Consequently, signatures are being incorporated into clinical practice and will soon influence everyday decisions in oncology. However, the slight overlap in the gene identity between signatures for the same cancer type or condition raises questions about their biological and clinical implications. To clarify these issues, better understanding of the molecular properties and possible interactions underlying apparently dissimilar signatures is needed. Here, we evaluated whether the signatures of 24 independent studies are related at the genome, transcriptome or proteome levels. Significant associations were consistently observed across these molecular layers, which suggest the existence of a common cancer cell phenotype. Convergence on cell proliferation and death supports the pivotal involvement of these processes in prognosis, metastasis and treatment response. In addition, functional and molecular associations were identified with the immune response in different cancer types and conditions that complement the contribution of cell proliferation and death. Examination of additional, independent, cancer datasets corroborated our observations. This study proposes a comprehensive strategy for interpreting cancer signatures that reveals common design principles and systems-level properties.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec575078
dc.identifier.issn1932-6203
dc.identifier.pmid19229342
dc.identifier.urihttps://hdl.handle.net/2445/96085
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0004544
dc.relation.ispartofPLoS One, 2009, vol. 4, num. 2, p. e4544
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0004544
dc.rightscc-by (c) Solé, X. et al., 2009
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationCàncer
dc.subject.classificationExpressió gènica
dc.subject.classificationMort cel·lular
dc.subject.classificationMetàstasi
dc.subject.otherCancer
dc.subject.otherGene expression
dc.subject.otherCell death
dc.subject.otherMetastasis
dc.titleBiological convergence of cancer signatureseng
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
575078.pdf
Mida:
1.26 MB
Format:
Adobe Portable Document Format